Leqembi Shows Promise in Stabilizing Early Alzheimer's Disease in Real-World Study
A real-world study presented at the Alzheimer's Association International Conference 2026 has shown promising results for the anti-amyloid therapy Leqembi (lecanemab) in treating early Alzheimer's disease. The study, involving 432 participants, found that over 75% of patients remained at the same stage of the disease after 17 months of treatment. Leqembi, approved by the FDA for early Alzheimer's, aims to reduce beta-amyloid plaques in the brain. The study highlights the potential of Leqembi to maintain clinical stability, allowing patients to preserve cognitive function and quality of life. 
